Trials / Terminated
TerminatedNCT00133224
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 408 (actual)
- Sponsor
- Cell Genesys · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases with pain. Patients may have had up to one prior non-taxane chemotherapy treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Immunotherapy allogeneic GM-CSF secreting cellular vaccine | Immunotherapy allogeneic GM-CSF secreting cellular vaccine |
| DRUG | Chemotherapy (docetaxel and prednisone) | Chemotherapy (docetaxel and prednisone) |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2008-08-01
- Completion
- 2009-06-01
- First posted
- 2005-08-23
- Last updated
- 2008-09-23
Locations
115 sites across 10 countries: United States, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00133224. Inclusion in this directory is not an endorsement.